Updates in the Frontline Treatment of Renal Cell Carcinoma: Guiding Pharmacists in Effective Management of Combination Therapies, featuring Patient Case Discussions

Program Description
Approximately 25% of patients with renal cell carcinoma (RCC) will present with metastatic disease at diagnosis, while up to half of patients with localized disease will eventually have disease progression including metastases during their disease course. Pharmacists practicing in oncology settings require knowledge about RCC histology and risk score, as these factors influence treatment options for patients. The treatment paradigm for metastatic RCC has greatly expanded and is shifting the prognosis for patients with the introduction of combination targeted therapies with immune checkpoint inhibitors (ICIs) and emerging ICI/vascular endothelial growth factor tyrosine kinase inhibitor combinations. However, toxicity profiles and immune-mediated adverse effects associated with use of these agents can increase treatment burden for patients and complicate disease management. This activity will feature patient case discussions to apply considerations for selection of frontline therapies and their ongoing management in patients. Additional challenges contributing to selection of therapy, management of adverse effects, and coordination of care for patients with RCC will be addressed.

Target audience: Health-system, oncology, and specialty pharmacists
Type of activity: Application
Release date: December 20, 2021
Expiration date: December 20, 2022
Time to complete activity: 1.5 hours
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Analyze recent evidence for frontline treatment of metastatic renal cell carcinoma (RCC)
• Identify therapy options based on recent guideline updates for frontline treatment of metastatic RCC considering patient- and disease-related factors
• Determine modifications for drug therapy for toxicity management in a patient receiving treatment for metastatic RCC with an immune checkpoint inhibitor/vascular endothelial growth factor tyrosine kinase inhibitor combination based on expert recommendations

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.5 contact hours (0.15 CEUs) under the ACPE universal activity number 0290-0000-21-442-H01-P. The activity is available for CE credit through December 20, 2022.

Instructions for Completing the Activity and Receiving CPE Credit

To receive CPE credit, participants must complete the pretest, view the webinar in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.

Disclosures

Faculty

Sherry L. Mori Vogt, PharmD, BCOP, has the following relevant financial relationship with a commercial interest to disclose:
Consultant: Exelixis advisory board participant

Allison Baxley, PharmD, BCOP, has no relevant financial relationships with commercial interests to disclose.

Pharmacy Times Continuing Education™ Planning Staff—Jim Palatine, RPh, MBA; Maryjo Dixon, RPh; Amy Seung, PharmD, BCOP, FHOPA; Crissy Wilson; Susan Pordon; Brianna Winters; and Chloe Taccetta have no relevant financial relationships with commercial interests to disclose.

Anonymous peer reviewers were used as part of content validation and conflict resolution. The peer reviewers have no relevant financial relationships with commercial interests to disclose.

Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms